Sino Biological has developed recombinant antigens for the 2025-2026 influenza vaccine strains. With the world's largest viral antigen collection, ProVir®, the company offers HA, NA, and NP proteins from all WHO-recommended vaccine strains of recent years. These antigens can be used to analyze vaccine-induced antibody response.
In addition, Sino Biological has also developed an extensive collection of monoclonal antibodies against flu antigens. These reagents can help facilitate relevant assay development.
